Multiparametric MR-PET Imaging Predicts Pharmacokinetics and Clinical Response to GDC-0084 in Patients with Recurrent High-Grade Glioma.

ABSTRACT:

Purpose

GDC-0084 is an oral, brain-penetrant small-molecule inhibitor of PI3K and mTOR. Because these two targets alter tumor vascularity and metabolism, respectively, we hypothesized multiparametric MR-PET could be used to quantify the response, estimate pharmacokinetic (PK) parameters, and predict progression-free survival (PFS) in patients with recurrent malignant gliomas.

Patients and methods

Multiparametric advanced MR-PET imaging was performed to evaluate physiologic response in a first-in-man, multicenter, phase I, dose-escalation study of GDC-0084 (NCT01547546) in 47 patients with recurrent malignant glioma.

Results

Measured maximum concentration (C _max) was associated with a decrease in enhancing tumor volume (P = 0.0287) and an incre

SUBMITTER: Ellingson BM 

PROVIDER: S-EPMC8204664 | biostudies-literature | 2020 Jul

REPOSITORIES: biostudies-literature